Figure 2
From: MiR-494 acts as a tumor promoter by targeting CASP2 in non-small cell lung cancer
MiR-494 protects cells against apoptosis induced by cisplatin. CCK8 was used in (a) A549 cells and (b) H460 cells with different concentrations of cisplatin. (c) CCK8 was used in A549 and H460 cells transfected with miR-494 or controlled with cisplatin (4 mg/L) (****P < 0.0001). (d) A549 and (e) H460 cells were transfected with miR-494 mimics or controls. Cells were treated with cisplatin (4 mg/L) for 24 hours. The apoptotic cells were measured through Annexin V-FITC and Propidium Iodine staining and analyzed with FACS. The percentage of Q2 and Q3 cells was measured as the apoptosis rate. Data are presented as the ± SD of three independent experiments (*P < 0.05).
